Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mavorixafor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 known ✓ | P61073 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mavorixafor SCHEMBL29379072 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL29932203 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL4716578 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL1288182 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL29701264 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508418 | 0.99 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2511014 | 0.99 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL3798687 | 0.99 | CXCR4 (0.98) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL14131151 | 0.97 | CXCR4 (0.95) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL30096707 | 0.97 | CXCR4 (0.95) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | claimed |
| EP-1730113-B1 | PROCESS FOR THE SYNTHESIS OF A CXCR4 ANTAGONIST | GENZYME CORP (US) | 2016-12-28 | — | — | EP | claimed |
| US-8211879-B2 | Cationic steroid antimicrobial compositions and methods of use | BRIGHAM YOUNG UNIVERSITY (US) | 2012-07-03 | — | — | US | claimed |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2008-07-10 | — | — | US | claimed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | claimed |
| EP-1730113-A1 | PROCESS FOR THE SYNTHESIS OF A CXCR4 ANTAGONIST | ANORMED INC. (CA) | 2006-12-13 | — | — | EP | claimed |
| WO-2005090308-A1 | PROCESS FOR THE SYNTHESIS OF A CXCR4 ANTAGONIST | ANORMED, INC. (CA) | 2005-09-29 | — | — | WO | claimed |
| US-20050209277-A1 | Process for the synthesis of CXCR4 antagonist | ANORMED CORPORATION (CA) | 2005-09-22 | — | — | US | claimed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2006020891-A2 | CHEMOKINE COMBINATIONS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | ANORMED INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050209277-A1 | Process for the synthesis of CXCR4 antagonist | ANORMED CORPORATION (CA) | 2005-09-22 | — | — | US | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-20050209277-A1 | Process for the synthesis of CXCR4 antagonist | CXCR4, CXCR1, CXCL12 | CXCR4 1/4885CHRM2 2228/4885CYP2D6 1779/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, VSIG8, CCR3 | CXCR4 61/4885CHRM2 3068/4885CYP2D6 3318/4885 |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | CXCL12, CXCR2, CXCR4 | CXCR4 3/4885CHRM2 2486/4885CYP2D6 4178/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CXCR4 3851/4885CHRM2 2728/4885CYP2D6 3755/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.